Chemistry: molecular biology and microbiology – Vector – per se
Patent
1996-01-23
1997-09-30
Guzo, David
Chemistry: molecular biology and microbiology
Vector, per se
536 234, 536 235, C12N 1562, C07H 2104
Patent
active
056725086
ABSTRACT:
The present invention pertains to novel inhibitors of cyclin-dependent kinases (CDKs), particularly CDK/cyclin complexes, which inhibitors can be used to control proliferation and/or differentiation of cells in which the inhibitors are introduced. More specifically, the inhibitors of the invention are chimeric proteins which include CDK-binding motifs from two or more different proteins. For example, the subject chimeric proteins can be generated from the in-frame fusion of coding sequences from two different CDK inhibitor proteins, such as may be derived from fusion of coding sequences for an INK4 protein and coding sequences for a CIP protein. Chimeric proteins of the present invention have been observed to be more potent inhibitors of cyclin/CDK complexes than were either of the portions of the chimeric protein individually.
REFERENCES:
Elledge, S. J. et al. (1994) "Cdk inhibitors: on the threshold of checkpoints and development" Curr Opin Cell Biol, vol. 6, pp. 847-852.
Guan K-L et al. (1994) "Growth suppression by p18, a p16 .sup.INK4/MTS1 and p14.sup.INK4BMTS2 related cdk6 inhibitor correlates with wild-type pRb function" Genes & Dev. vol. 8, pp. 2939-2952.
Hannon G. and Beach D. (1994) "p15.sup.INK4B is a potential effector of TGF-.beta.-induced cell cycle arrest" Nature, vol. 371, pp. 257-261.
Harper J. et al. (1994) "The p21 cdk-interacting protein cip1 is a potenmt inhibitor of G1 cyclin-dependent kinases" Cell, vol. 75, pp. 805-816.
Hiral H. et al. (1995) "novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases cdk4 and cdk6" Moll Cell Biol, vol. 15, No. 5, pp. 2672-2681.
Kamb A. et al (1994) "A cell cycle regulatory potentially involved in genesis of many tumor types" Science, vol. 264, pp. 436-440.
Lee M-H. et al. (1995) "Cloning of p57.sup.KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution" Genes & Dev. vol. 9; pp. 639-649.
Marx J. (1994) "New tumor suppressor may rival p53" Science vol. 264, pp. 344-345.
Matsuoka S. et al. (1995) "p57.sup.KIP2, a structurally distinct member of the p21.sup.CIP1 cdk inhibitor family, is a candidate tumor suppressor gene" Genes & Dev vol. 9; pp. 650-662.
Ming Chan, F.K. et al. (1995) "Identification of human and mouse p19, a novel cdk4 and cdk6 inhibitor with homology to p16.sup.INK4 " Mol Cell Biol, vol. 15, No. 5; pp. 2682-2688.
Ogawa N. et al. (1995) "Functional domains of Pho81p, an inhibitor of Pho85p protein kinase, in the transduction pathway of Pi signals in Saccharomyces cerevisiae" Mol Cell Biol, vol.15, No. 2; pp. 997-1004.
Polyak K. et al. (1994) "p27.sup.Kip 1, a cyclin-cdk inhibitor, links transforming growth factor .beta. and contact inhibition to cell cycle arrest." Genes & Dev. vol. 8; pp. 9-22.
Serrano M et al. (1993) "A new regulatory motif in celi-cycle control causing specific inhibition of cyclin D/cdk4" Nature, vol. 366, pp. 704-707.
Xiong Y. et al. (1993) "Subunit rearrangement of the cyclin-dependent kinases is associated with cellular transformation" Genes & Dev. vol. 7, pp. 1572-1583.
Xiong, Y. et al. (1993) "p21 is a universal inhibitor of cyclin kinases" Nature, vol. 366, p. 701-704.
Zhu et. al. p107 uses a p21CIP1-related domain to biind cyclin/cdk2 adn regulate interactions with E2F. Genes and Devel. vol. 9:1740-1752. Sep. 1995.
Beach David
Gyuris Jeno
Lamphere Lou
Arnold Beth E.
Guzo David
Mitotix, Inc.
Sandals William
Vincent Matthew P.
LandOfFree
Inhibitors of cell-cycle progression, and uses related thereto does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of cell-cycle progression, and uses related thereto, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of cell-cycle progression, and uses related thereto will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2256167